These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8624345)

  • 1. Hormone replacement therapy and cardiovascular disease: the human model.
    Sullivan JM
    Br J Obstet Gynaecol; 1996 May; 103 Suppl 13():59-65; discussion 66-7. PubMed ID: 8624345
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prevention of cardiovascular diseases by hormone replacement in postmenopause].
    Windler E
    Zentralbl Gynakol; 1996; 118(4):188-97. PubMed ID: 8651005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone replacement therapy and cardiovascular risk].
    Maffei S; De Caterina R
    G Ital Cardiol; 1996 Aug; 26(8):899-940. PubMed ID: 9005173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmenopausal hormone therapy and the cardiovascular system.
    Speroff L; Lobo RA
    Heart Dis Stroke; 1994; 3(3):173-6. PubMed ID: 8044433
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen-receptor polymorphism and hormone-replacement therapy.
    Garrido JA
    N Engl J Med; 2002 Sep; 347(10):762-3; author reply 762-3. PubMed ID: 12213951
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
    Shlipak MG; Chaput LA; Vittinghoff E; Lin F; Bittner V; Knopp RH; Hulley SB;
    Am Heart J; 2003 Nov; 146(5):870-5. PubMed ID: 14597937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogens for heart disease: a report from the annual session of the American College of Cardiology.
    Wehrmacher WH; Messmore H;
    J Gend Specif Med; 2000; 3(6):21-2. PubMed ID: 11253378
    [No Abstract]   [Full Text] [Related]  

  • 8. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol.
    Grover SA; Dorais M; Coupal L
    Epidemiology; 2003 May; 14(3):315-20. PubMed ID: 12859032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of early estrogen replacement therapy on microvascular reactivity in patients after bilateral ovarectomy.
    Prázný M; Fait T; Vrablik M
    Neuro Endocrinol Lett; 2007 Aug; 28(4):496-501. PubMed ID: 17693976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen: risk versus benefit for the prevention of coronary artery disease.
    LaRosa JC
    Coron Artery Dis; 1993 Jul; 4(7):588-94. PubMed ID: 8281363
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
    Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance.
    Erenus M; Karakoç B; Gürler A
    Climacteric; 2001 Sep; 4(3):228-34. PubMed ID: 11588947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.